Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 108

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 108
---
 for loss or damage
suffered and is intended to punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular
facts of the case as well as the laws and treaties in effect at the time. The United States and the United Kingdom do not currently have
a treaty providing for the mutual recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We
are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we file Annual
Reports and other information with the SEC. As a foreign private issuer, we are exempt from, among other things, the rules under the Exchange
Act prescribing the furnishing and content of proxy statements and our officers, directors and principal shareholders are exempt from
the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.

The SEC maintains a web site
that contains reports and information statements and other information about issuers, such as us, who file electronically with the SEC.
The address of that website is www.sec.gov.

This prospectus and any prospectus
supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration
statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the documents establishing
the terms of the offered securities are or may be filed as exhibits to the registration statement of which this prospectus forms a part.
Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all
respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of
the relevant matters. You may inspect a copy of the registration statement through the SEC’s website, as provided above.

We also maintain a website
at www.biodexapharma.com through which you can access our SEC filings. The information set forth on our website is not
part of this prospectus.

| 61 |

<div align='center'>INCORPORATION OF DOCUMENTS BY REFERENCE</div>

The SEC allows us to “incorporate
by reference” the information we file with the SEC, which means that we can disclose important information to you by referring you
to another document filed separately with the SEC. The information incorporated by reference is an important part of this prospectus.
We